FILTER

Refine your search with the following facets to narrow down your results.

6 Current news of Galapagos Genomics

Finalists For the European Biotechnica Award 2010 Named

16-Aug-2010 - The names of the finalists in this year’s European Biotechnica Award have been announced. The companies Addex Pharmaceuticals (Switzerland), Apeiron Biologics (Austria) and Galapagos Genomics (Belgium) have made it through to the final round. Addex Pharmaceuticals, based in Plan-Les-Ouates (near ...

anxiety Belgium Biotechnica +7

Galapagos, Amsterdam Molecular Therapeutics, Netherlands Institute for Brain Research and Vrije Universiteit Amsterdam cooperate

19-Sep-2005 - Galapagos, Amsterdam Molecular Therapeutics B.V. (AMT), the Netherlands Institute for Brain Research (NIBR), and the Vrije Universiteit Amsterdam (VUA) announce their collaboration to develop innovative treatments for acute spinal cord and peripheral nerve damage (neurotrauma). The research ...

functional genomics Galapagos gene therapies +4

Galapagos NV, ZoBio BV, Pyxis Discovery BV and Leiden University collaborate in arthritis drug discovery program

11-Aug-2005 - Galapagos NV, ZoBio BV, Pyxis Discovery BV and Leiden University announced the formation of a four-way collaboration to pursue a small molecule drug discovery program in the area of arthritis. The collaboration, funded in part by an IS ("Innovatiesubsidie Samenwerkingsprojecten") grant from the ...

biology chemistry compound libraries +3

Galapagos and Celera Genomics sign gene function analysis agreement

21-Jun-2005 - Galapagos announced that it has entered into a services agreement with Celera Genomics Group, an Applera Corporation business. Under the agreement, Galapagos' services division Galadeno will provide technology and adenoviral reagents enabling Celera to analyze gene function in human cells and ...

Applera Celera Galapagos +4

Cystic Fibrosis Foundation Therapeutics and Galapagos Initiate Alliance to Discover Drug Targets

18-Apr-2005 - Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), and Galapagos have initiated a two-year target discovery alliance. The organizations will apply Galapagos' adenoviral siRNA (SilenceSelect®) and cDNA (FLeXSelect®) collections and expertise in assay design to discover and validate novel drug ...

cystic fibrosis diseases food +5

Wyeth selects novel drug targets in osteoporosis collaboration with Galapagos Genomics NV

10-Nov-2004 - Galapagos Genomics announced that it has reached a research milestone in its osteoporosis discovery program with Wyeth Pharmaceuticals, the pharmaceutical division of Wyeth. Within the program, which was initiated November 2003, Galapagos has used its osteoporosis disease expertise in combination ...

biology Galapagos milestone payments +2